Anti-cancer drugs play a pivotal role in the ongoing battle against cancer, working tirelessly at the cellular level to impede the growth and spread of malignant cells. These medications encompass a diverse array, from chemotherapy to targeted therapies, each designed to thwart the unique characteristics of cancer cells. By interfering with specific molecular processes, these drugs aim to halt the relentless progression of the disease. In recent years, ground-breaking advancements in the development of anti-cancer drugs have emerged, offering more targeted and effective treatment options.
Precision medicine, a paradigm shift in cancer therapy, tailors these drugs to the genetic makeup of individual tumors, optimizing therapeutic outcomes while minimizing side effects. Despite the challenges, ongoing research and innovation continue to redefine the landscape of anti-cancer drugs, bringing hope and resilience to those affected by this formidable adversary. As the field evolves, the quest for more potent and personalized therapies remains a driving force in the relentless pursuit of a cancer-free future.
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Bernd Blobel
University of Regensburg, Germany
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Srividya Narayanan
Northeastern University, United States
Maria Richards Brown
University College London, United Kingdom
Rassa Pegahi
UPSA, France
Hanieh Khalili
University of East London, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia